Dependence on Specific Pipelines and Partnership Agreements and Revenue Uncertainty
First written in FY2017. 4 of 8 entries say "Restated". Latest entry: FY2026.
SanBio moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The Group operates businesses under a revenue model based on joint development with major pharmaceutical companies and the out-licensing of marketing rights, as well as an in-house sales model under which the Group obtains marketing approval, builds a sales structure and sells products itself.」
The uncertainty associated with multiple revenue models, including the in-house sales model as well as dependence on licensing revenue from specific partners, has been identified. - FY2023RestatedAnnual report
「The Group intends to out-license multiple pipelines in the future to reduce the uncertainty of this revenue model. However, monetization of those pipelines will also be uncertain and dependent on development progress」
The policy of out-licensing multiple pipelines to reduce dependence on specific partnerships and pipelines, and the uncertainty of monetization because it depends on development progress, have been reaffirmed. - FY2021Policy of diversifying across multiple pipelinesAnnual report
「The Group intends to out-license multiple pipelines in the future to reduce the uncertainty of this revenue model. However, monetization of those pipelines will also be uncertain and dependent on development progress, and delays in their development could have a material impact on the Group's operating results and financial position.」
A policy of out-licensing multiple pipelines was presented as a means of reducing earnings uncertainty arising from dependence on specific partnerships and pipelines. However, the associated monetization is also identified as a risk because it depends on development progress. - FY2020RestatedAnnual report
「For the SB623 chronic ischemic stroke program being jointly advanced with 大日本住友製薬株式会社 in the United States, joint development was discontinued in December 2019, and the joint development and licensing agreement with 大日本住友製薬株式会社 was terminated at the same time.」
The termination of the agreement with 大日本住友製薬株式会社 reaffirmed the actual materialization of dependence on a specific partner and on revenue from the agreement. - FY2020-Q3MaterialisedAnnual report
「Following a detailed analysis of the Phase 2b clinical trial of this product, 大日本住友製薬株式会社 decided to discontinue joint development after reviewing its priorities under its company-wide business strategy.」
An actual event occurred in which the partner discontinued joint development of the SB623 chronic ischemic stroke program in North America, on which the business plan depended, after the primary endpoint was not achieved. - FY2020-Q1RestatedAnnual report
「Against this backdrop, revenue including development support payments received under the Group's joint development and marketing license agreement with 大日本住友製薬株式会社 for SB623 in North America」
Dependence on the SB623 joint development and marketing license agreement with 大日本住友製薬株式会社 in North America and on revenue under the agreement has been reaffirmed. - FY2019RestatedAnnual report
「With respect to SB623, a regenerative cell medicine under development for ischemic stroke, the Group has entered into a collaboration agreement with 大日本住友製薬株式会社 covering joint development and the out-licensing of marketing rights in the United States and Canada, and has a business revenue plan centered on revenue from this agreement.」
Dependence on the collaboration agreement with 大日本住友製薬株式会社 for SB623 for ischemic stroke and on revenue from that agreement, as well as the uncertainty of milestone revenue, has been reaffirmed. - FY2017First statedAnnual report
「With respect to SB623, a regenerative cell medicine under development for ischemic stroke, the Group has out-licensed development and marketing rights in Japan to TEIJIN LIMITED and in the United States and Canada to 大日本住友製薬株式会社, respectively, and has a business revenue plan centered on revenue from these licensing agreements.」
The Company discloses its dependence on licensing agreement revenue for SB623 for ischemic stroke, the possibility that the agreements may end, and the uncertainty of milestone revenue, which depends on development progress.